重组腺病毒转染膀胱移行上皮预防膀癌复发的实验研究

Bladder cancer is the sixth most common malignancies in our country and both its incidence and prevalence are rising. Furthermore, the recurrence rates are high (50 to 80% of the patients), and 10 to 25% of the initial superficial tumors ultimately progress to muscle invasion and have a worse prognosis.Intravesical bacillus Calmette-Guerin (BCG) immunotherapy is currently the most effective treatment for superficial transitional cell carcinoma (TCC) of the urinary bladder. 30% of patients not responding to BCG . Many studies have shown the advantage of adjuvant treatment(intra-vesical instillation of mitomycin ) in decreasing the recurrence rate of bladder tumours.but some patients are experiencing considerable toxicities. In recent years, the actual mechanism by which BCG exerts its antitumor effect still needs detailed unraveling ,It has stimulated studies addressing either the development of improved BCG treatment schedules or the exploration of the therapeutic value of a series of (novel) biological response modifiers, like interferons (IFNs), interleukin (IL- 2). Intravesical instillation of interleukin-2 is an effective method for preventing the recurrence of bladder cancer. In this study, we engineered recombinant interleukin-2 (rIL-2) and transferred IL-2 gene to transitional cells of bladder. Bladder tumors were induced in female Wistar rats by intravesical irrigation of the carcinogen N-methyl-nitrosourea (MNU) and N-(4-5-nitro-2-furyl)-2-thiazoly formamide ( BBN).We investigated intravesical instillation of recombinant interleukin-2 to prevent the recurrence of bladder cancer by bladder cancer models.

以腺病毒为载体，应用IL-2及IFN-r基因转染小鼠膀胱上皮细胞，在体内及体外分别观察IL-2及IFN-r目的基因的表达。在目的基因理想表达基础上，用N-正丁基-N-4-羟基丁基亚硝胺茄∈蠼螂装┠Ｐ停⒂冒螂坠嘧⒎椒ǎü锬Ｐ脱芯恐刈橄俨《咎迥谧拘∈蟀螂咨掀ぴし腊螂装└捶⒌淖饔谩Ｄ康氖墙⒒蜃景螂咨掀ぴし腊螂装┓椒ǎτ糜诹俅病